Short Communication - Journal of Cell Biology and Metabolism (2025) Volume 7, Issue 3

Glucose Transporters in Health and Disease: From Cellular Mechanisms to Therapeutic Targets

Department of Biochemistry, Shanghai Metabolic Research Center, China.

*Corresponding Author:

Lian Zhou
Department of Biochemistry
Shanghai Metabolic Research Center, China
E-mail: Water@durham.ac.uk

Received: 03-Jun-2025, Manuscript No. AACBM-25-166664; Editor assigned: 04-Jun-2025, PreQC No. AACBM-25-1666645(PQ); Reviewed: 18-Jun-2025, QC No AACBM-25-1666645; Revised: 21-Jun-2025, Manuscript No. AACBM-25-1666645(R); Published: 28-Jun-2025, DOI:10.35841/aacbm-7.3.268

Citation: Zhou L. Glucose transporters in health and disease: From cellular mechanisms to therapeutic targets. J Cell Biol Metab. 2025;7(3):268.

Introduction

Glucose is a fundamental energy source for nearly all cells in the body, playing a central role in cellular metabolism, biosynthesis, and homeostasis. As a hydrophilic molecule, glucose cannot freely diffuse across the lipid bilayer of cell membranes and requires specialized transport proteins known as glucose transporters. These proteins enable the regulated uptake and distribution of glucose to maintain physiological energy balance [1]. The family of glucose transporters, primarily the facilitative glucose transporters (GLUTs) and sodium-glucose co-transporters (SGLTs), are essential in orchestrating glucose flux across various tissues. Dysregulation of glucose transport is implicated in a broad spectrum of diseases, including diabetes, cancer, neurodegeneration, and cardiovascular disorders. Understanding the cellular mechanisms governing glucose transport and its pathological alterations provides crucial insights into disease processes and unveils potential therapeutic targets [2].

The facilitative glucose transporter (GLUT) family, encoded by the SLC2A gene family, comprises 14 identified isoforms (GLUT1–14), each with distinct tissue distribution, substrate specificity, and regulatory mechanisms. These transporters facilitate passive diffusion of glucose along its concentration gradient and are integral to both basal and insulin-regulated glucose uptake [3]. GLUT1 is ubiquitously expressed and responsible for basal glucose uptake in many tissues, including erythrocytes, endothelial cells, and the blood-brain barrier. GLUT2 is found in hepatocytes, pancreatic β-cells, and renal tubular cells, characterized by its high-capacity, low-affinity glucose transport, allowing it to act as a glucose sensor. GLUT3, with a high affinity for glucose, is predominantly expressed in neurons, reflecting the brain's high energy demands. GLUT4, found mainly in adipose tissue and skeletal muscle, is unique due to its insulin-regulated translocation from intracellular vesicles to the plasma membrane, a key mechanism for postprandial glucose clearance [4].

In parallel, the sodium-glucose co-transporters (SGLTs), encoded by the SLC5A gene family, mediate active glucose transport by coupling glucose uptake with sodium ion gradients. SGLT1 is primarily expressed in the small intestine and renal proximal tubules, where it plays a crucial role in dietary glucose absorption and renal glucose reabsorption. SGLT2, located predominantly in the kidney, reabsorbs the majority of filtered glucose from the glomerular filtrate. This mechanism is vital for maintaining systemic glucose levels and preventing glycosuria under normal physiological conditions [5].

The regulation of glucose transporters is intricately linked to hormonal signals, cellular energy status, and environmental cues. Insulin, a major anabolic hormone, stimulates the translocation of GLUT4 to the plasma membrane, thereby enhancing glucose uptake in muscle and adipose tissue. This process involves a cascade of signaling events initiated by insulin receptor activation, leading to the phosphorylation of insulin receptor substrates (IRS) and subsequent activation of the phosphoinositide 3-kinase (PI3K)/Akt pathway. Akt phosphorylates AS160, facilitating the mobilization and fusion of GLUT4-containing vesicles with the plasma membrane. The failure of this mechanism is a hallmark of insulin resistance and type 2 diabetes mellitus [6].

In pathological states such as diabetes, the expression and function of glucose transporters are profoundly altered. In type 1 diabetes, characterized by autoimmune destruction of pancreatic β-cells and absolute insulin deficiency, GLUT4 translocation is impaired due to the lack of insulin signaling. In type 2 diabetes, insulin resistance leads to reduced GLUT4 activity despite hyperinsulinemia. Moreover, chronic hyperglycemia can induce glucotoxicity, altering GLUT expression and promoting oxidative stress and inflammation. Studies have shown that in diabetic patients, there is a downregulation of GLUT4 in skeletal muscle and adipose tissue, contributing to impaired glucose disposal and exacerbating hyperglycemia [7].

Conversely, certain GLUTs are upregulated in disease states, notably in cancer. Tumor cells exhibit a high rate of glycolysis even under normoxic conditions, a metabolic reprogramming known as the Warburg effect. This heightened glycolytic flux demands increased glucose uptake, which is achieved through overexpression of specific GLUTs, particularly GLUT1 and GLUT3. The overexpression of GLUT1 has been observed in various cancers, including breast, lung, colorectal, and gliomas. This not only fuels the rapid proliferation of cancer cells but also contributes to resistance against hypoxia and apoptosis. GLUT1 expression is often regulated by oncogenic signaling pathways and transcription factors such as HIF-1α, c-Myc, and PI3K/Akt, which drive its transcription under conditions of metabolic stress. Consequently, GLUT1 has emerged as a biomarker for tumor aggressiveness and a potential target for anticancer therapies [8].

SGLT transporters are also implicated in disease, particularly in the context of renal glucose handling and cardiovascular risk. In diabetes, SGLT2-mediated glucose reabsorption in the proximal tubule is often enhanced, contributing to persistent hyperglycemia and increasing the renal threshold for glucose. This has led to the development of SGLT2 inhibitors, a novel class of antidiabetic drugs that block glucose reabsorption, promoting glucosuria and lowering blood glucose levels. Beyond glycemic control, SGLT2 inhibitors have demonstrated significant benefits in reducing cardiovascular mortality and slowing the progression of diabetic nephropathy, making them a valuable tool in managing diabetic complications [9].

Neurological disorders also reflect the importance of glucose transporters. The brain depends almost exclusively on glucose for energy, and any disruption in glucose transport can have profound effects. GLUT1 deficiency syndrome, a rare genetic disorder caused by mutations in the SLC2A1 gene, leads to impaired glucose transport across the blood-brain barrier, resulting in developmental delays, seizures, and motor dysfunction. Treatment strategies such as ketogenic diets, which provide alternative fuel sources like ketone bodies, can partially compensate for the energy deficit. Similarly, altered GLUT3 expression has been implicated in neurodegenerative diseases like Alzheimer’s disease, where reduced glucose uptake in the brain precedes cognitive decline. Positron emission tomography (PET) imaging using fluorodeoxyglucose (FDG) has been employed to visualize these metabolic changes in affected brain regions [10].

Conclusion

In conclusion, glucose transporters are vital components of cellular metabolism, enabling the precise regulation of glucose uptake and utilization in health and disease. Their diverse isoforms are intricately regulated by hormonal, metabolic, and environmental signals, aligning cellular energy demands with physiological needs. Aberrant expression and function of glucose transporters underlie a wide array of pathological conditions, from metabolic disorders and cancer to neurodegeneration and immune dysfunction. The expanding knowledge of transporter biology and regulation has paved the way for innovative therapeutic strategies, positioning glucose transporters as promising targets in the management of chronic and acute diseases. Continued research into their mechanisms and interactions holds great promise for improving human health through more effective and tailored interventions.

References

1. Thorens B, Mueckler M. Glucose transporters in the 21st Century. American Journal of Physiology-Endocrinology and Metabolism. 2010;298(2):E141-5.

Indexed at, Google Scholar, Cross Ref

2. Navale AM, Paranjape AN. Glucose transporters: physiological and pathological roles. Biophys Rev. 2016;8(1):5-9.

Indexed at, Google Scholar, Cross Ref

3. Bell GI, Kayano T, Buse JB, et al. Molecular biology of mammalian glucose transporters. Diabetes care. 1990;13(3):198-208.

Indexed at, Google Scholar, Cross Ref

4. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr. 2003;89(1):3-9.

Indexed at, Google Scholar, Cross Ref

5. Brown GK. Glucose transporters: structure, function and consequences of deficiency. Journal of inherited metabolic disease. 2000;23:237-46.

Indexed at, Google Scholar, Cross Ref

6. Medina RA, Owen GI. Glucose transporters: expression, regulation and cancer. Biol Res. 2002;35(1):9-26.

Indexed at, Google Scholar, Cross Ref

7. Szablewski L. Expression of glucose transporters in cancers. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2013;1835(2):164-9.

Indexed at, Google Scholar, Cross Ref

8. Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics. 2007;8(2):113-28.

Indexed at, Google Scholar, Cross Ref

9. Klip A, Tsakiridis T, Marette A, et al. Regulation of expression of glucose transporters by glucose: a review of studies in vivo and in cell cultures. The FASEB journal. 1994;8(1):43-53.

Indexed at, Google Scholar, Cross Ref

10. TETAUD E, BARRETT MP, BRINGAUD F, et al. Kinetoplastid glucose transporters. Biochem J. 1997;325(3):569-80.

Indexed at, Google Scholar, Cross Ref